항응고제 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of anticoagulants Market

The global anticoagulants market size was valued at USD 41.41 billion in 2025. The market is projected to grow from USD 45.51 billion in 2026 to USD 97.09 billion by 2034, exhibiting a strong CAGR of 9.93% during the forecast period (2026-2034). North America dominated the global market with a 50.70% share in 2025, driven by the high prevalence of cardiovascular diseases and strong product innovation.

Anticoagulants, commonly known as blood thinners, play a critical role in preventing and treating cardiovascular diseases (CVDs) by reducing the formation of blood clots. With cardiovascular disorders such as heart attacks, strokes, pulmonary embolism, and deep vein thrombosis rising globally, demand for advanced anticoagulant therapies continues to grow.

Market Drivers

Rising Prevalence of Cardiovascular Diseases

Cardiovascular diseases remain one of the leading causes of mortality worldwide. According to global health estimates, a large percentage of deaths related to CVD are caused by heart attacks and strokes. Anticoagulants are essential in managing these conditions by preventing clot formation and reducing complications. Increasing awareness about heart health and preventive treatment significantly supports market expansion.

Innovation in Novel Oral Anticoagulants (NOACs)

The introduction of novel oral anticoagulants (NOACs), such as apixaban and rivaroxaban, has transformed treatment approaches. These advanced drugs offer improved safety profiles and convenience compared to traditional therapies. Strong sales performance of leading products like Eliquis and Xarelto continues to fuel overall market revenue growth.

Market Segmentation Analysis

By Disease Indication

The market is segmented into pulmonary embolism (PE), deep vein thrombosis (DVT), atrial fibrillation (AF), heart attacks, and others.

The pulmonary embolism (PE) segment is expected to dominate, holding a 76.34% share in 2026. In 2025, this segment generated USD 31.53 billion in revenue, reflecting high treatment demand. Rising obesity, cancer prevalence, and sedentary lifestyles are key contributors to PE incidence.

The DVT and atrial fibrillation segments also show strong growth due to increasing diagnosis rates and long-term therapy requirements. The heart attack segment remains significant, as anticoagulants are essential in secondary prevention.

By Route of Administration

Based on administration route, the market is divided into oral and injectable.

The oral segment is projected to lead with an 85.58% share in 2026, owing to patient convenience, strong product pipeline, and higher adoption of NOACs. Injectable anticoagulants, including warfarin and heparin-based drugs, maintain steady demand in hospital settings but face competition from oral alternatives.

By Distribution Channel

The market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.

The hospital pharmacies segment is expected to hold a 46.04% share in 2026, as anticoagulants require careful prescription and monitoring. Retail pharmacies follow closely due to refill convenience, while online pharmacies are projected to witness the fastest growth rate due to increasing digital adoption.

Regional Insights

North America

North America accounted for USD 20.98 billion in 2025 and grew to USD 23.3 billion in 2026. The region is expected to maintain dominance throughout the forecast period. The U.S. market alone was valued at USD 21.74 billion in 2026. High cardiovascular disease prevalence, obesity rates, and strong R&D initiatives drive regional growth.

Europe

Europe is anticipated to grow at a CAGR of 7.6% during the forecast period. The UK market reached USD 2.05 billion in 2026, while Germany accounted for USD 3.25 billion in 2026. Rising mortality from cardiovascular disorders supports market demand.

Asia Pacific

Asia Pacific is expected to witness the highest growth rate. Japan's market reached USD 3.21 billion in 2025 and USD 3.56 billion in 2026. China recorded USD 2.56 billion in 2026 and is projected to grow at a strong CAGR of 13.40%. Increasing healthcare expenditure and awareness are major growth factors.

Latin America and the Middle East & Africa are projected to experience steady growth due to improving healthcare infrastructure and rising disease prevalence.

Competitive Landscape

Leading players in the anticoagulants market include Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., and Eisai Co., Ltd. These companies dominate through strong product portfolios, strategic acquisitions, and continuous R&D investments. However, increasing generic competition may moderate pricing power in certain regions.

Conclusion

The global anticoagulants market demonstrates strong and sustained growth, rising from USD 41.41 billion in 2025 to a projected USD 97.09 billion by 2034, supported by a CAGR of 9.93%. Increasing cardiovascular disease prevalence, growing awareness, and innovation in novel oral anticoagulants are key growth drivers. While North America leads in revenue share, Asia Pacific is emerging as the fastest-growing region. Continuous R&D, strategic partnerships, and expansion into developing markets will be critical for companies aiming to strengthen their competitive position through 2034.

Segmentation By Disease Indication

• Pulmonary Embolism (PE)
• Deep Vein Thrombosis (DVT)
• Atrial Fibrillation
• Heart Attacks
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Major Cardiovascular Diseases by Key Countries
• 4.2. Overview of Novel Oral Anticoagulants (NOACs)
• 4.3. Pipeline Analysis
• 4.4. Key Industry Developments Such as Mergers & Acquisitions
• 4.5. New Product Launches
• 4.6. Regulatory Scenario in Key Countries
• 4.7. Reimbursement Scenario by Key Countries

5. Global Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.2.1. Pulmonary Embolism (PE)
  • 5.2.2. Deep Vein Thrombosis (DVT)
  • 5.2.3. Atrial Fibrillation
  • 5.2.4. Heart Attacks
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Injectable
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospitals Pharmacies
  • 5.4.2. Retail Pharmacies
  • 5.4.3. Online Pharmacies
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Country
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Disease Indication
  • 6.2.1. Pulmonary Embolism (PE)
  • 6.2.2. Deep Vein Thrombosis (DVT)
  • 6.2.3. Atrial Fibrillation
  • 6.2.4. Heart Attacks
  • 6.2.5. Others
• 6.3. Market Analysis - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Injectable
• 6.4. Market Analysis - By Distribution Channel
  • 6.4.1. Hospitals Pharmacies
  • 6.4.2. Retail Pharmacies
  • 6.4.3. Online Pharmacies
  • 6.4.4. Others
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Disease Indication
  • 7.2.1. Pulmonary Embolism (PE)
  • 7.2.2. Deep Vein Thrombosis (DVT)
  • 7.2.3. Atrial Fibrillation
  • 7.2.4. Heart Attacks
  • 7.2.5. Others
• 7.3. Market Analysis - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Injectable
• 7.4. Market Analysis - By Distribution Channel
  • 7.4.1. Hospitals Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Online Pharmacies
  • 7.4.4. Others
• 7.5. Market Analysis - By Country
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Disease Indication
  • 8.2.1. Pulmonary Embolism (PE)
  • 8.2.2. Deep Vein Thrombosis (DVT)
  • 8.2.3. Atrial Fibrillation
  • 8.2.4. Heart Attacks
  • 8.2.5. Others
• 8.3. Market Analysis - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Injectable
• 8.4. Market Analysis - By Distribution Channel
  • 8.4.1. Hospitals Pharmacies
  • 8.4.2. Retail Pharmacies
  • 8.4.3. Online Pharmacies
  • 8.4.4. Others
• 8.5. Market Analysis - By Country
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Disease Indication
  • 9.2.1. Pulmonary Embolism (PE)
  • 9.2.2. Deep Vein Thrombosis (DVT)
  • 9.2.3. Atrial Fibrillation
  • 9.2.4. Heart Attacks
  • 9.2.5. Others
• 9.3. Market Analysis - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Injectable
• 9.4. Market Analysis - By Distribution Channel
  • 9.4.1. Hospitals Pharmacies
  • 9.4.2. Retail Pharmacies
  • 9.4.3. Online Pharmacies
  • 9.4.4. Others
• 9.5. Market Analysis - By Country
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Disease Indication
  • 10.2.1. Pulmonary Embolism (PE)
  • 10.2.2. Deep Vein Thrombosis (DVT)
  • 10.2.3. Atrial Fibrillation
  • 10.2.4. Heart Attacks
  • 10.2.5. Others
• 10.3. Market Analysis - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Injectable
• 10.4. Market Analysis - By Distribution Channel
  • 10.4.1. Hospitals Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
  • 10.4.4. Others
• 10.5. Market Analysis - By Country
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
  • 11.4.1. Bristol-Myers Squibb Company
    • 11.4.1.1. Overview,
    • 11.4.1.2. Products & services,
    • 11.4.1.3. SWOT analysis,
    • 11.4.1.4. Recent developments,
    • 11.4.1.5. strategies,
    • 11.4.1.6. financials (based on availability)
  • 11.4.2. Pfizer Inc.
    • 11.4.2.1. Overview,
    • 11.4.2.2. Products & services,
    • 11.4.2.3. SWOT analysis,
    • 11.4.2.4. Recent developments,
    • 11.4.2.5. strategies,
    • 11.4.2.6. financials (based on availability)
  • 11.4.3. Bayer AG
    • 11.4.3.1. Overview,
    • 11.4.3.2. Products & services,
    • 11.4.3.3. SWOT analysis,
    • 11.4.3.4. Recent developments,
    • 11.4.3.5. strategies,
    • 11.4.3.6. financials (based on availability)
  • 11.4.4. Janssen Pharmaceuticals, Inc.
    • 11.4.4.1. Overview,
    • 11.4.4.2. Products & services,
    • 11.4.4.3. SWOT analysis,
    • 11.4.4.4. Recent developments,
    • 11.4.4.5. strategies,
    • 11.4.4.6. financials (based on availability)
  • 11.4.5. Eisai Co., Ltd.
    • 11.4.5.1. Overview,
    • 11.4.5.2. Products & services,
    • 11.4.5.3. SWOT analysis,
    • 11.4.5.4. Recent developments,
    • 11.4.5.5. strategies,
    • 11.4.5.6. financials (based on availability)
  • 11.4.6. Other Prominent Players
    • 11.4.6.1. Overview,
    • 11.4.6.2. Products & services,
    • 11.4.6.3. SWOT analysis,
    • 11.4.6.4. Recent developments,
    • 11.4.6.5. strategies,
    • 11.4.6.6. financials (based on availability)

12. Strategic Recommendations